Literature DB >> 19422539

Regional distribution of TDP-43 inclusions in Alzheimer disease (AD) brains: their relation to AD common pathology.

Ai Kadokura1, Tsuneo Yamazaki, Cynthia A Lemere, Masamitsu Takatama, Koichi Okamoto.   

Abstract

Initially, trans activation responsive region (TAR)-DNA-binding protein 43 (TDP-43) was considered to be a disease-specific component of ubiquitin-positive and tau-negative inclusions in the brains of patients with frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) and amyotrophic lateral sclerosis (ALS); however, it is now widely known that this protein also abnormally accumulates in neurons in other neurodegenerative diseases. On the basis of observation mainly in the medial temporal lobe, TDP-43-immunoreactive neuronal inclusions have been detected in 20-30% of Alzheimer disease (AD) brains. However, it is controversial whether these cases represent a combined disease, that is, mixed AD/FTLD-U. To address this issue, it is necessary to obtain more knowledge on the region-specific distribution of TDP-43 immunoreactivity and also about its relationship to AD common pathology. Here, we describe abnormal TDP-43 immunoreactivity in the medial temporal lobe in 5/16 AD patients (31%). Most of the depositions were cytoplasmic inclusions, mainly located in the subiculum and parahippocampal gyrus and rarely in dentate granular cells of the hippocampus. TDP-43-positive inclusions and senile plaque/neurofibrillary tangle distribution were not always identical, and intracellular colocalizations of TDP-43 and phospho-tau were also infrequent. The cases showing TDP-43-positive inclusions in the medial temporal lobe also showed abnormally highly dense TDP-43 immunoreactivity in the frontal, but not in the parietal and occipital cortices. Intracellularly, TDP-43-positive inclusions were highly ubiquitinated and colocalized with p62 immunoreactivity as well. Our findings suggest that abnormal TDP-43 deposition and AD pathology (formation of senile plaques and neurofibrillary tangles) might occur independently. However, taken together with the results of previous reports, the distribution of TDP-43 immunoreactivity in the hippocampus and frontal cortex in AD appear to be varying. We consider that it is still too early to determine that the TDP-43 accumulation is a part of AD pathology or result from a completely independent pathology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19422539     DOI: 10.1111/j.1440-1789.2009.01017.x

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  40 in total

1.  Detergent Insoluble Proteins and Inclusion Body-Like Structures Immunoreactive for PRKDC/DNA-PK/DNA-PKcs, FTL, NNT, and AIFM1 in the Amygdala of Cognitively Impaired Elderly Persons.

Authors:  Jozsef Gal; Jing Chen; Yuriko Katsumata; David W Fardo; Wang-Xia Wang; Sergey Artiushin; Douglas Price; Sonya Anderson; Ela Patel; Haining Zhu; Peter T Nelson
Journal:  J Neuropathol Exp Neurol       Date:  2018-01-01       Impact factor: 3.685

Review 2.  On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia.

Authors:  F Geser; D Prvulovic; L O'Dwyer; O Hardiman; P Bede; A L W Bokde; J Q Trojanowski; H Hampel
Journal:  Prog Neurobiol       Date:  2011-09-03       Impact factor: 11.685

3.  TDP-43 interacts with pathological τ protein in Alzheimer's disease.

Authors:  Sandra O Tomé; Luis A Gomes; Xiaohang Li; Rik Vandenberghe; Thomas Tousseyn; Dietmar Rudolf Thal
Journal:  Acta Neuropathol       Date:  2021-04-02       Impact factor: 17.088

4.  Positive florbetapir PET amyloid imaging in a subject with frequent cortical neuritic plaques and frontotemporal lobar degeneration with TDP43-positive inclusions.

Authors:  Geidy E Serrano; Marwan N Sabbagh; Lucia I Sue; Jose A Hidalgo; Julie A Schneider; Barry J Bedell; Vivianna M Van Deerlin; Eunran Suh; Haruhiko Akiyama; Abhinay D Joshi; Michael J Pontecorvo; Mark A Mintun; Thomas G Beach
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 5.  The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases.

Authors:  Peter T Nelson; Erin L Abner; Ela Patel; Sonya Anderson; Donna M Wilcock; Richard J Kryscio; Linda J Van Eldik; Gregory A Jicha; Zsombor Gal; Ruth S Nelson; Bela G Nelson; Jozsef Gal; Md Tofial Azam; David W Fardo; Matthew D Cykowski
Journal:  J Neuropathol Exp Neurol       Date:  2018-01-01       Impact factor: 3.685

6.  Accumulation of transactive response DNA binding protein 43 in mild cognitive impairment and Alzheimer disease.

Authors:  Cyntia Tremblay; Isabelle St-Amour; Julie Schneider; David A Bennett; Frédéric Calon
Journal:  J Neuropathol Exp Neurol       Date:  2011-09       Impact factor: 3.685

7.  Overlapping but distinct TDP-43 and tau pathologic patterns in aged hippocampi.

Authors:  Vanessa D Smith; Adam D Bachstetter; Eseosa Ighodaro; Kelly Roberts; Erin L Abner; David W Fardo; Peter T Nelson
Journal:  Brain Pathol       Date:  2017-03-24       Impact factor: 6.508

8.  TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia.

Authors:  Bryan D James; Robert S Wilson; Patricia A Boyle; John Q Trojanowski; David A Bennett; Julie A Schneider
Journal:  Brain       Date:  2016-11-01       Impact factor: 13.501

9.  TDP-43 Neuropathologic Associations in the Nun Study and the Honolulu-Asia Aging Study.

Authors:  Margaret E Flanagan; Brenna Cholerton; Caitlin S Latimer; Laura S Hemmy; Steven D Edland; Kathleen S Montine; Lon R White; Thomas J Montine
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

10.  TAR DNA-binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features.

Authors:  Keith A Josephs; Jennifer L Whitwell; Nirubol Tosakulwong; Stephen D Weigand; Melissa E Murray; Amanda M Liesinger; Leonard Petrucelli; Matthew L Senjem; Robert J Ivnik; Joseph E Parisi; Ronald C Petersen; Dennis W Dickson
Journal:  Ann Neurol       Date:  2015-09-16       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.